The European Commission (EC) has approved the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.
Read more here: http://ecancer.org/news/12480-european-approval-of-lutetium-oxodotreotide-for-gastroenteropancreatic-neuroendocrine–gep-net–tumours.php